` 302550 (Remed Co Ltd) vs KOSPI 200 Comparison - Alpha Spread

R
302550
vs
K
KOSPI 200

Over the past 12 months, Remed Co Ltd has underperformed KOSPI 200, delivering a return of +3% compared to the KOSPI 200's +114% growth.

Stocks Performance
302550 vs KOSPI 200

Loading
302550
KOSPI 200
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
302550 vs KOSPI 200

Loading
302550
KOSPI 200
Difference
www.alphaspread.com

Performance By Year
302550 vs KOSPI 200

Loading
302550
KOSPI 200
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Remed Co Ltd vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Remed Co Ltd
Glance View

Market Cap
100.2B KRW
Industry
Health Care

REMED Co., Ltd. is engaged in the manufacturing of other medical equipment. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2018-08-14. The firm is involved in the manufacturing and sale of transcranial magnetic stimulation (TMS) therapy machines, pain therapy machines, electrosurgical units as well as biosignal and monitoring machines. The pain therapy machines include electromagnetic stimulation machines, extracorporeal shockwave therapy machines and high intensity laser therapy machines, among others. The biosignal and monitoring machines include patient monitors, fetal monitors, electrocardiogram (ECG/EKG) machines, among others. The firm distributes its products within the domestic market and to overseas markets.

Intrinsic Value
2 202.26 KRW
Overvaluation 31%
Intrinsic Value
Price
R
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett